Zygomycete infection following voriconazole prophylaxis.
van Well
Gijs T J
GT
Department of Paediatric Infectious Diseases, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands. g.vanwell@vumc.nl
van Groeningen
Iris
I
Debets-Ossenkopp
Yvette J
YJ
van Furth
A Marceline
AM
Zwaan
C Michel
CM
D000293:Adolescent; D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D025141:Drug Resistance, Fungal; D017809:Fatal Outcome; D006801:Humans; D016867:Immunocompromised Host; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D011743:Pyrimidines / Q000627:therapeutic use*; D012233:Rhizopus / Q000187:drug effects / Q000254:growth & development; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole; D020096:Zygomycosis / Q000188:drug therapy / Q000517:prevention & control*
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole